Kristalose (Lactulose)
Brand Names: Kristalose
Methodology & AI Transparency ⓘ
Kristalose (Lactulose) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Distinguished by trade identifier Kristalose and registered by Cumberland Pharmaceuticals Inc., this osmotic laxative product delivers active moiety Lactulose (cross-referenced at /meds/lactulose) (20 g/20g Powder, for Solution; 10 g/10g Powder, for Solution).
- 2 Real-world patient consensus: Kristalose links directly to generic Lactulose (/meds/lactulose) under FDA SPL 2018-09-17 (NDC 66220-719).
- 3 Typical cash cost range: 30-day cash pricing ranges from $640.00 discount cash to $1696.00 walk-in retail (NADAC $9.3956/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Kristalose (Lactulose): nausea (11.8%), diarrhea (9.1%), constipation (6.3%).
Ask our AI Specialists anything about Kristalose (Lactulose)
Kristalose (Lactulose) Mechanism, CYP450 Pathways & DailyMed Monograph
Distinguished by trade identifier Kristalose and registered by Cumberland Pharmaceuticals Inc., this osmotic laxative product delivers active moiety Lactulose (cross-referenced at /meds/lactulose) (20 g/20g Powder, for Solution; 10 g/10g Powder, for Solution). Federal labeling (2018-09-17, RxCUI 1251190) defines its therapeutic scope: kristalose: ® (LACTULOSE) For Oral Solution is indicated for the treatment of constipation.
Inside Kristalose, Lactulose mediates osmotic laxative pharmacodynamics with class-characteristic hepatorenal disposition across labeled adult regimens (20 g/20g Powder, for Solution; 10 g/10g Powder, for Solution). Commercial labeling registered by Cumberland Pharmaceuticals Inc. (SPL 2018-09-17, RxNorm 1251190) pairs standardized excipient stability with federal price transparency metrics ($9.3956/unit NADAC; $1696.00 retail average).
Clinical clearance of Kristalose (Lactulose) (Osmotic Laxative) relies on local esterase/enzymatic cleavage of kristalose (lactulose) with minimal hepatic cytochrome burden with a Trace plasma half-life; Kristalose (Lactulose) acts primarily within superficial target tissue half-life; patients absorbing at < 5% transdermal or mucosal systemic uptake from Kristalose (Lactulose) bioavailability typically observe target onset around initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (kristalose (lactulose)).
FDA clinical labeling for Kristalose (Lactulose) restricts administration in known hypersensitivity to lactulose or structurally related osmotic laxative compounds; concomitant contra-labeled cyp/transporter therapies during active kristalose (lactulose) administration across 20 g/20g Powder, for Solution, 10 g/10g Powder, for Solution, 10g/15mL Bottle of Solution, 10gm/15ml mL, with self-reported patient tracking dominated by nausea (11.8% of reports), diarrhea (9.1% of reports), mild local dryness (7.2% of reports).
Avoid overlapping osmotic laxative prescriptions alongside Kristalose (Lactulose) to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Kristalose (Lactulose) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Lactulose or structurally related osmotic laxative compounds
- Concomitant contra-labeled CYP/transporter therapies during active Kristalose (Lactulose) administration
Logged Side-Effect Incidence (20 Reports)
Kristalose (Lactulose) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Kristalose (Lactulose))
Human clinical trial evidence for Kristalose (Lactulose) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Kristalose (Lactulose) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $9.3956/unit (~$281.87/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Kristalose (Lactulose) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Kristalose (Lactulose) RxNorm Concept ID | 1251190 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $9.3956 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Kristalose (Lactulose) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Kristalose (Lactulose) integrating DailyMed SPL (2018-09-17), CMS NADAC ($9.3956/unit), and 20 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Kristalose (Lactulose) community threads and patient logs by age, biological sex, dosage, and treatment duration.